Lopinavir/ritonavir - Wikipedia
网页Lopinavir/ritonavir (LPV/r), sold under the brand name Kaletra among others, is a fixed-dose combination antiretroviral medication for the treatment and prevention of HIV/AIDS. [4] It combines lopinavir with a low dose of ritonavir. [4] It is generally recommended for use with other antiretrovirals. [4]
Efficacy and safety of lopinavir-ritonavir in COVID-19: A …
网页2021年4月20日 · Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been evaluated.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid ...
网页2020年3月18日 · To evaluate the efficacy and safety of oral lopinavir–ritonavir for SARS-CoV-2 infection, we conducted a randomized, controlled, open-label trial, LOTUS China (Lopinavir Trial for Suppression...
NEJM官方翻译丨中国团队洛匹那韦-利托那韦治疗重症COVID-19
网页2020年3月19日 · 利托那韦与洛匹那韦联用可通过抑制细胞色素P450来延长洛匹那韦的血浆半衰期。. 2004年发表的一项开放标签研究提示，与仅接受利巴韦林治疗的历史对照组相比，利巴韦林加用洛匹那韦-利托那韦（分别为400 mg和100 mg）降低了SARS患者的不良临床结局（急性呼吸 ...
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A …
网页2020年6月30日 · Lopinavir (LPV) is an antiretroviral protease inhibitor used in combination with ritonavir (booster) in HIV infection therapy and prevention. LPV is a peptidomimetic HIV type 1 aspartate protease inhibitor that acts by binding to its catalytic site, thereby, preventing the cleavage of viral polyprotein precursors into mature, functional ...
Lopinavir–ritonavir in patients admitted to hospital with COVID …
网页Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19.
Efficacy and Safety of Lopinavir/Ritonavir for Treatment of …
网页2020年11月28日 · Lopinavir-ritonavir (LPV/RTV) is a protease inhibitor and nucleoside analog combination used for human immunodeficiency virus (HIV-1) and was also thought to be a potential treatment for COVID-19 [8], as its therapeutic value in the treatment of COVID-19 was assessed by in-vitro studies that claimed inhibition of …
Lopinavir-ritonavir for COVID-19: A living systematic review
网页2020年7月15日 · For severe and critical patients with COVID-19, lopinavir/ritonavir might play a role in improving outcomes, but the available evidence is still limited. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.
Lopinavir–ritonavir in severe COVID-19 - Nature Medicine
网页2020年4月9日 · A randomized, controlled, open-label trial of lopinavir–ritonavir in patients with severe COVID-19 shows no benefit for the primary endpoint beyond standard care but shows benefit for some ...
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ...
网页2020年5月30日 · Early triple antiviral therapy was safe and superior to lopinavir–ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.